{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:20:46Z","timestamp":1794061246877,"version":"4.8.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Tumor-associated macrophages (TAMs) are central to tumor progression, immune suppression, and resistance to therapy, making them promising targets in cancer immunotherapy. TAMs exhibit functional heterogeneity, polarizing into pro-tumor (M2-like) and anti-tumor (M1-like) phenotypes under different microenvironmental cues. M2-like TAMs promote immune evasion, angiogenesis, and metastasis, while M1-like TAMs enhance antitumor immunity. Combining TAM-targeted therapies with immune checkpoint inhibitors is also emerging as a potential strategy to enhance immunotherapy efficacy. This review outlines TAM-mediated immunosuppression mechanisms, including the secretion of VEGF, TGF-\u03b2, and immune checkpoint molecules like PD-L1. We also summarize the current strategies targeting TAMs, such as blocking the CD47\/SIRP\u03b1 axis, using CD40 agonists, and PI3K\u03b3 inhibitors, which have shown promise in preclinical studies. Overall, this review underscores TAMs as pivotal therapeutic targets and proposes future directions to optimize combinatorial immunotherapy for enhanced clinical outcomes.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1658795","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:13:47Z","timestamp":1756268027000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Progress in targeting tumor-associated macrophages in cancer immunotherapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Wanqiu","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"152666","DOI":"10.1016\/j.semarthrit.2025.152666","article-title":"Immunotherapy in cancer","author":"Zeiser","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"B4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","article-title":"Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/Anti-CTLA-4 combined therapy","volume":"35","author":"Gide","year":"2019","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01432-0","article-title":"A STT3A-dependent PD-L1 glycosylation modification mediated by GMPS drives tumor immune evasion in hepatocellular carcinoma","volume":"32","author":"Guo","year":"2025","journal-title":"Cell Death Differ"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507283","article-title":"CD8(+) T cell exhaustion in the tumor microenvironment of breast cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37060","article-title":"Eliminating a barrier: Aiming at VISTA, reversing MDSC-mediated T cell suppression in the tumor microenvironment","volume":"10","author":"Deng","year":"2024","journal-title":"Heliyon"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.029697","article-title":"Glycogen metabolism-mediated intercellular communication in the tumor microenvironment influences liver cancer prognosis","volume":"32","author":"Zhang","year":"2024","journal-title":"Oncol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.11.009","article-title":"Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy","volume":"99","author":"Komohara","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"B12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12864-023-09421-2","article-title":"Identification of novel prognostic circRNA biomarkers in circRNA-miRNA-mRNA regulatory network in gastric cancer and immune infiltration analysis","volume":"24","author":"Yan","year":"2023","journal-title":"BMC Genomics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.02.003","article-title":"Targeting tumor-associated macrophages in cancer","volume":"40","author":"Pathria","year":"2019","journal-title":"Trends Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"4485","DOI":"10.1038\/s41467-024-48637-y","article-title":"C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"107986","DOI":"10.1016\/j.pharmthera.2021.107986","article-title":"Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach","volume":"231","author":"Chamseddine","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0218","article-title":"DKK1 promotes tumor immune evasion and impedes anti-PD-1 treatment by inducing immunosuppressive macrophages in gastric cancer","volume":"10","author":"Shi","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.32604\/or.2023.043481","article-title":"Application of exosomal miRNA mediated macrophage polarization in colorectal cancer: Current progress and challenges","volume":"32","author":"Zhang","year":"2023","journal-title":"Oncol Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101032","DOI":"10.1016\/j.jhepr.2024.101032","article-title":"Oxytocin alleviates liver fibrosis via hepatic macrophages","volume":"6","author":"Zhai","year":"2024","journal-title":"JHEP Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12864-023-09209-4","article-title":"Multi-level integrative analysis of the roles of lncRNAs and differential mRNAs in the progression of chronic pancreatitis to pancreatic ductal adenocarcinoma","volume":"24","author":"Zhao","year":"2023","journal-title":"BMC Genomics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2017.11.001","article-title":"Macrophages: Their role, activation and polarization in pulmonary diseases","volume":"223","author":"Arora","year":"2018","journal-title":"Immunobiology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16465","article-title":"Regulation of intrinsic and extrinsic metabolic pathways in tumour-associated macrophages","volume":"290","author":"Davuluri","year":"2023","journal-title":"FEBS J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-01061-6","article-title":"Roles of macrophages in tumor development: a spatiotemporal perspective","volume":"20","author":"Bied","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2009.07448.x","article-title":"Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer","volume":"277","author":"Mitsudomi","year":"2010","journal-title":"FEBS J"},{"key":"B28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s13402-019-00453-z","article-title":"Tumor-associated macrophages: role in cancer development and therapeutic implications","volume":"42","author":"Salmaninejad","year":"2019","journal-title":"Cell Oncol (Dordr)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2018.03.006","article-title":"Macrophages: the road less traveled, changing anticancer therapy","volume":"24","author":"Guerriero","year":"2018","journal-title":"Trends Mol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.029638","article-title":"ScRNA-seq reveals the correlation between M2 phenotype of tumor-associated macrophages and lymph node metastasis of breast cancer","volume":"31","author":"Shen","year":"2023","journal-title":"Oncol Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-019-0976-4","article-title":"Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis","volume":"18","author":"Wei","year":"2019","journal-title":"Mol Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/17435889.2025.2525057","article-title":"Near-infrared II nanomaterials for hypoxic TME diagnosis and therapy","volume":"20","author":"Cai","year":"2025","journal-title":"Nanomedicine (Lond)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12943-022-01645-2","article-title":"The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies","volume":"21","author":"Bai","year":"2022","journal-title":"Mol Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adq5226","article-title":"NF-\u03baB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironment","volume":"10","author":"de la Calle-Fabregat","year":"2024","journal-title":"Sci Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.96831","article-title":"Hypoxic tumor-derived exosomal miR-4488 induces macrophage M2 polarization to promote liver metastasis of pancreatic neuroendocrine neoplasm through RTN3\/FABP5 mediated fatty acid oxidation","volume":"20","author":"Lu","year":"2024","journal-title":"Int J Biol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12964-022-00872-w","article-title":"M2 macrophage-secreted exosomes promote metastasis and increase vascular permeability in hepatocellular carcinoma","volume":"21","author":"Lu","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2017.10.050","article-title":"The effect of neoadjuvant chemotherapy on the correlation of tumor-associated macrophages with CD31 and LYVE-1","volume":"223","author":"Mitrofanova","year":"2018","journal-title":"Immunobiology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84427","article-title":"The impact of hypoxia on tumor-associated macrophages","volume":"126","author":"Henze","year":"2016","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S531190","article-title":"Cinobufagin inhibits invasion and migration of non-small cell lung cancer via regulating glucose metabolism reprogramming in tumor-associated macrophages","volume":"19","author":"Sun","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"156784","DOI":"10.1016\/j.cyto.2024.156784","article-title":"Neutrophil-derived IL-10 increases CVB3-induced acute pancreatitis pathology via suppressing CD8(+)T cell activation while increasing macrophage STAT3-IL-6 cascade","volume":"184","author":"Yang","year":"2024","journal-title":"Cytokine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"111680","DOI":"10.1016\/j.cellsig.2025.111680","article-title":"FOXC1 promotes EMT and colorectal cancer progression by attracting M2 macrophages via the TGF-\u03b2\/Smad2\/3\/snail pathway","volume":"130","author":"Zhang","year":"2025","journal-title":"Cell Signal"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202207668","article-title":"Three-in-One oncolytic adenovirus system initiates a synergetic photodynamic immunotherapy in immune-Suppressive cholangiocarcinoma","volume":"19","author":"Wang","year":"2023","journal-title":"Small"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3390\/biomedicines11061768","article-title":"Clinical significance of PD-L1 status in circulating tumor cells for cancer management during immunotherapy","volume":"11","author":"Strati","year":"2023","journal-title":"Biomedicines"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-018-2997-3","article-title":"Tumor-associated macrophages: a short compendium","volume":"76","author":"Prenen","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.10.037","article-title":"Metabolic changes in tumor cells and tumor-associated macrophages: A mutual relationship","volume":"413","author":"Netea-Maier","year":"2018","journal-title":"Cancer Lett"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/iej.14229","article-title":"An HRL-SC\/HIF-1\u03b1 positive feedback loop enhances cell proliferation, migration and angiogenesis in dental pulp stem cells via PI3K\/AKT signalling pathway","volume":"58","author":"Zeng","year":"2025","journal-title":"Int Endod J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13046-025-03321-x","article-title":"MMP28 recruits M2-type tumor-associated macrophages through MAPK\/JNK signaling pathway-dependent cytokine secretion to promote the Malignant progression of pancreatic cancer","volume":"44","author":"Dong","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"101856","DOI":"10.1016\/j.bonr.2025.101856","article-title":"VEGF-A, -C, -D, VEGFR1, -2, -3, PDGF-BB and FGF-2 join forces to induce vascular and lymphatic angiogenesis during bone healing of hip implants","volume":"26","author":"Cassuto","year":"2025","journal-title":"Bone Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2418752122","article-title":"Adenosine diphosphate stimulates VEGF-independent choroidal endothelial cell proliferation: A potential escape from anti-VEGF therapy","volume":"122","author":"Biswas","year":"2025","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B51","doi-asserted-by":"publisher","first-page":"118023","DOI":"10.1016\/j.biopha.2025.118023","article-title":"Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights","volume":"186","author":"Mahaki","year":"2025","journal-title":"BioMed Pharmacother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1537631","article-title":"The role of intestinal macrophage polarization in colitis-associated colon cancer","volume":"16","author":"Deng","year":"2025","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"216801","DOI":"10.1016\/j.canlet.2024.216801","article-title":"Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages","volume":"590","author":"Dong","year":"2024","journal-title":"Cancer Lett"},{"key":"B54","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/imt-2016-0135","article-title":"Tumor-associated macrophages: implications in cancer immunotherapy","volume":"9","author":"Petty","year":"2017","journal-title":"Immunotherapy"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-0330","article-title":"Are TEMs canceled? Questioning the functional relevance of tie2-expressing macrophages","volume":"82","author":"Zhang","year":"2022","journal-title":"Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-3181","article-title":"Tie2 receptor in tumor-infiltrating macrophages is dispensable for tumor angiogenesis and tumor relapse after chemotherapy","volume":"82","author":"Jakab","year":"2022","journal-title":"Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2014.09.035","article-title":"Targeting the Angiopoietin-2\/Tie-2 axis in conjunction with VEGF signal interference","volume":"380","author":"Biel","year":"2016","journal-title":"Cancer Lett"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1303585","article-title":"TIE-2 expressing monocytes in human cancers","volume":"6","author":"Turrini","year":"2017","journal-title":"Oncoimmunology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1042\/CS20160129","article-title":"Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems","volume":"131","author":"Eklund","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41467-017-02610-0","article-title":"Angiogenic factor-driven inflammation promotes extravasation of human proangiogenic monocytes to tumours","volume":"9","author":"Sidibe","year":"2018","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40364-023-00473-w","article-title":"HMGA1 augments palbociclib efficacy via PI3K\/mTOR signaling in intrahepatic cholangiocarcinoma","volume":"11","author":"Li","year":"2023","journal-title":"biomark Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"101096","DOI":"10.1016\/j.neo.2024.101096","article-title":"\u03b2-Catenin mediated TAM phenotype promotes pancreatic cancer metastasis via the OSM\/STAT3\/LOXL2 axis","volume":"60","author":"Zhang","year":"2025","journal-title":"Neoplasia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160392","article-title":"S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3\/IL-1\u03b2","volume":"214","author":"Weichand","year":"2017","journal-title":"J Exp Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.7150\/jca.1.126","article-title":"Inhibition of hypoxia-induced cell motility by p16 in MDA-MB-231 breast cancer cells","volume":"1","author":"Li","year":"2010","journal-title":"J Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12943-019-1102-3","article-title":"Harnessing tumor-associated macrophages as aids for cancer immunotherapy","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nature13862","article-title":"Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis","volume":"515","author":"Bonapace","year":"2014","journal-title":"Nature"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Invest New Drugs"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2019.03.013","article-title":"CXCL12\/CXCR4 pathway orchestrates CSC-like properties by CAF recruited tumor associated macrophage in OSCC","volume":"378","author":"Li","year":"2019","journal-title":"Exp Cell Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0170","article-title":"Post-Sepsis state induces tumor-Associated macrophage accumulation through CXCR4\/CXCL12 and favors tumor progression in mice","volume":"4","author":"Mota","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2326-6066.CIR-15-0170","article-title":"CX3CL1 signaling in the tumor microenvironment","volume":"1231","author":"Conroy","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgy177","article-title":"Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma","volume":"40","author":"Carminati","year":"2019","journal-title":"Carcinogenesis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pharmthera.2015.11.008","article-title":"Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials","volume":"158","author":"Van Acker","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-14-0621","article-title":"Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer","volume":"5","author":"Junankar","year":"2015","journal-title":"Cancer Discov"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00774","article-title":"Complementing the cancer-immunity cycle","volume":"10","author":"Pio","year":"2019","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0787","article-title":"Intracellular factor H drives tumor progression independently of the complement cascade","volume":"9","author":"Daugan","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0891","article-title":"Tumor cells hijack macrophage-Produced complement C1q to promote tumor growth","volume":"7","author":"Roumenina","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182124","article-title":"Specific targeting of CD163(+) TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression","volume":"216","author":"Etzerodt","year":"2019","journal-title":"J Exp Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B83","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2020.06.032","article-title":"Coupled scRNA-Seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer","volume":"182","author":"Katzenelenbogen","year":"2020","journal-title":"Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2019.9848","article-title":"Escherichia coli promotes DSS\u2212induced murine colitis recovery through activation of the TLR4\/NF\u2212\u03baB signaling pathway","volume":"19","author":"Lu","year":"2019","journal-title":"Mol Med Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1039\/C9FO01490J","article-title":"Habitual animal fat consumption in shaping gut microbiota and microbial metabolites","volume":"10","author":"Wan","year":"2019","journal-title":"Food Funct"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00271.2016","article-title":"A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease","volume":"311","author":"Wright","year":"2016","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/nature21409","article-title":"Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages","volume":"543","author":"Guerriero","year":"2017","journal-title":"Nature"},{"key":"B90","doi-asserted-by":"publisher","first-page":"111605","DOI":"10.1016\/j.biopha.2021.111605","article-title":"CAR-macrophage: A new immunotherapy candidate against solid tumors","volume":"139","author":"Chen","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03495-z","article-title":"CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial","volume":"31","author":"Reiss","year":"2025","journal-title":"Nat Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658795\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T04:13:48Z","timestamp":1756268028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658795\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":92,"alternative-id":["10.3389\/fimmu.2025.1658795"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1658795","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"article-number":"1658795"}}